Cross-linked N-telopeptide of type I collagen predicts bone metastasis in lung cancer
Elevated levels of cross-linked N-telopeptide of type I collagen (NTx) appear to raise the risk of development and progression of bone metastasis (BM) in lung cancer patients, a recent study reveals.
The research team performed a meta-analysis of 11 studies (n=1,108) that compared the expression levels of NTx between lung cancer patients with and without BM. Aside from a review of study references, the databases of Web of Science, CNKI, Wangfang, PubMed and Embase were accessed for the present study.
Pooled findings from eight studies showed that patients positive for BM had significantly higher serum NTx concentrations than their BM-negative counterparts (weighted mean difference [WMD], -11.57 percent; 95 percent CI, -15.14 to -8.00).
Similarly, urinary levels of NTx, investigated in three studies, were also found to be significantly higher in patients with BM than those without (WMD, -65.15 percent; -88.33 to -41.97).
The pooled sensitivity and specificity of serum NTx in discerning BM from non-BM lung cancer patients were 0.74 (0.67 to 0.79) and 0.85 (0.80 to 0.89), respectively. In comparison, the corresponding values for urinary NTx were 0.77 (0.67 to 0.86) and 0.81 (0.76 to 0.86).
Both serum and urinary NTx had similar and good diagnostic accuracy, with respective diagnostic odds ratios of 15.07 (9.6 to 23.65) and 15.25 (8.38 to 27.73). The respective areas under the receiver operating curve for both were 0.8889 and 0.8655, which suggests that both samples could accurately distinguish between patients with and without BM.